<DOC>
	<DOCNO>NCT02984397</DOCNO>
	<brief_summary>Our goal conduct proof-of-concept trial test efficacy KF treatment adolescent severe CWP respond standard care ( SOC ) treatment program multidisciplinary tertiary care chronic pain clinic . The change associate intervention ( KF placebo ) quantify use Patients ' Global Impression Change ( PGIC ) scale 16 week treatment . Secondary , aim evaluate effect KF pain sensitivity , physical emotional functioning , also explore potential biological underlie mechanism .</brief_summary>
	<brief_title>Chronic Widespread Pain White Blood Cell Activation</brief_title>
	<detailed_description>We design proof-of-concept ( POC ) trial compose three arm . The first two arm randomize , control , double-blind , parallel-group study , design ass potential efficacy KF treatment pain associate symptom adolescent CWP . The third arm consist assess standard care ( SOC ) data patient wish participate study , agree allow u use SOC data compare patient participate study . This arm help evaluate potential beneficial effect part study ( `` placebo '' effect ) receive new treatment condition SOC limit success rate .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<criteria>Female male adolescent age 14 18 year old ; For female adolescent child bear potential : negative serum pregnancy test base line screening ; For female adolescent child bear potential : willing able use contraceptive method duration study 30 day receive last dose study drug ; Diffuse body pain present least 3 month , also symptoms fatigue , sleep disturbance , cognitive change mood disorder ; Accompanied least one somatic symptom variable degree include irritable bowel syndrome , headache , menstrual pain , low urinary tract symptom , myofascial pain , temporomandibular pain ; Symptoms explain illness ; Physical examination within normal limit except tenderness pressure soft tissue ( i.e . tactile hyperalgesia increase pain follow painful stimulus ) Overall body pain average score â‰¥ 4 Moderate severe physical impairment Functional Disability Inventory &gt; 12 point . Stable dose his/her current medication least four week Not significant change health condition ( PIGS less 6 point ) 8 week treatment Be part trial ; Have specific diagnosis explain symptom ; include rheumatoid arthritis , systemic lupus erythematosus , scleroderma and/or connective tissue disease Refuse donate blood sample ; Not able fill electronic record ; Cognitive impairment interfere clinical evaluation ; Known intolerance allergy KF ; Been treatment mast cell stabilizer agent ; Seizures history actual treatment ; Coagulopathies chronic thrombocytopenia ; Atopic dermatitis ( eczema ) chronic urticaria ( hive ) Schizophrenia bipolar disorder Elective surgery within study timeline Abnormal lab result ( i.e. , elevate SGPT low platelet count , low Hb Ht ) last 6 month base line evaluation Patients pregnant breastfeeding ; Patients oral antidiabetic agent ;</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>pain</keyword>
	<keyword>ketotifen</keyword>
	<keyword>pediatric</keyword>
	<keyword>mast cell</keyword>
</DOC>